Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study.
Recently, it has been shown that FCGR3A-158 gene polymorphism is associated with biological and possibly clinical response to infliximab in Crohn's disease. We further assessed this association in a subset of 344 patients from the large and well-defined cohort of 573 patients with Crohn's disease from the ACCENT I study. No association could be observed between FCGR3A-158 gene polymorphism and the clinical response to infliximab, which was primarily defined as a decrease of >or=70 points in the Crohn's disease activity index or clinical remission (Crohn's disease activity index <150). We did, however, confirm a trend towards a greater decrease in C-reactive protein after infliximab in V/V homozygotes as compared with V/F heterozygotes and F/F homozygotes (-79.4, -76.5, and -64.3%, respectively, at week 6; P=0.085; one-tailed P=0.043). This finding has no immediate clinical impact but may enhance the understanding of the complex mechanisms of action of anti-tumor necrosis factor agents in Crohn's disease.
Louis
Edouard J
EJ
Department of Gastroenterology, CHU and University of Liège, Liège, Belgium. Edouard.louis@ulg.ac.be
Watier
Hervé E
HE
Schreiber
Stefan
S
Hampe
Jochen
J
Taillard
François
F
Olson
Allan
A
Thorne
Nicole
N
Zhang
Hongyan
H
Colombel
Jean-Frédéric
JF
D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001483:Base Sequence; D003424:Crohn Disease / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D017931:DNA Primers / Q000235:genetics; D005260:Female; D005838:Genotype; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D017452:Receptors, IgG / Q000235:genetics*
D000911:Antibodies, Monoclonal; D017931:DNA Primers; C496124:FCGR3A protein, human; D017452:Receptors, IgG; D000069285:Infliximab